Blood Pressure Monitoring During BTK Inhibitor Treatment
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study uses a connected blood pressure monitor to track blood pressure changes in patients with blood cancers who are starting a type of targeted drug called a BTK inhibitor. Researchers want to see if home monitoring helps catch and manage blood pressure changes early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with one of these blood cancers: chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, or mantle cell lymphoma
- You are starting a BTK inhibitor drug (ibrutinib, acalabrutinib, or zanubrutinib) for the first time or after a previous treatment ended
- You have reliable internet access at home
- You have the ability to understand and remember study instructions without significant cognitive support
- You are enrolled in a social security or health insurance system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
This study looks at whether starting certain blood cancer treatments (BTK inhibitors or others like venetoclax) affects heart rhythm. It focuses on people with specific blood cancers who are starting a new treatment, to check for new or worsening atrial fibrillation.
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
Hear when a new Waldenstrom Macroglobulinaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.